Abstract | BACKGROUND: This phase I study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics and antitumor activity of ganetespib in patients with solid malignancies. METHODS: Patients were enrolled in cohorts of escalating ganetespib doses, given as 1 hour IV infusion, once weekly for 3 weeks, followed by a 1-week rest until disease progression or unacceptable toxicity. Endpoints included safety, pharmacokinetic and pharmacodynamic parameters and preliminary clinical activity. RESULTS: Fifty-three patients were treated at doses escalating from 7 to 259 mg/m(2). The most common adverse events were Grade 1 and 2 diarrhea, fatigue, nausea or vomiting. Dose-limiting toxicities (DLT) observed were: one Grade 3 amylase elevation (150 mg/m(2)), one Grade 3 diarrhea and one Grade 3 and one Grade 4 asthenia (259 mg/m(2)). The MTD was 216 mg/m(2) and the recommended phase 2 dose was established at 200 mg/m(2) given IV at Days 1, 8, and 15 every 4 weeks. There was a linear relationship between dose and exposure. Plasma HSP70 protein levels remained elevated for over a week post treatment. Disease control rate (objective response and stable disease at ≥ 16 weeks) was 24.4%. CONCLUSIONS:
Ganetespib is well tolerated as a weekly infusion for 3 of every 4 weeks cycle. The recommended phase II dose is 200 mg/m(2), and is associated with an acceptable tolerability profile. TRIAL REGISTRATION: NCT00687934.
|
Authors | Jonathan W Goldman, Robert N Raju, Gregory A Gordon, Iman El-Hariry, Florentina Teofilivici, Vojo M Vukovic, Robert Bradley, Michael D Karol, Yu Chen, Wei Guo, Takayo Inoue, Lee S Rosen |
Journal | BMC cancer
(BMC Cancer)
Vol. 13
Pg. 152
(Mar 25 2013)
ISSN: 1471-2407 [Electronic] England |
PMID | 23530663
(Publication Type: Clinical Trial, Phase I, Journal Article)
|
Chemical References |
- HSP90 Heat-Shock Proteins
- STA 9090
- Triazoles
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Drug Administration Schedule
- Female
- HSP90 Heat-Shock Proteins
(antagonists & inhibitors, blood)
- Humans
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Staging
- Neoplasms
(drug therapy, metabolism)
- Treatment Outcome
- Triazoles
(administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
|